MILFORD, Pa., March 11, 2015
/PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO),
today announced Manzo Pharmaceuticals has identified Medicus
Research to perform the human clinical study of Lacto-Freedom
probiotic, a necessary step in order to take the ground breaking
product to market.
The goal of this human study is to use science to substantiate
that the Lacto-Freedom™ Probiotic demonstrates efficacy in
decreasing symptoms of Lactose Intolerance when consuming a glass
of milk. Dr. Jay Udani, CEO of
Medicus Reseach, concurred that the FDA recognizes genetically
modified probiotics, like Lacto-Freedom probiotic, as nutritional
supplements and there are no additional regulations that pertain to
genetically modified probiotics. Dr. Jay Udeni has expertise in FDA
regulations, probiotics development and deployment, clinical
studies, as well as Federal Trade Commission regulation compliance.
Medicus Research designs its clinical trials to guarantee that its
studies are structurally and functionally compliant, and follow the
strict guidelines that are in place. Medicus has established Good
Clinical Practice and FDA compliant procedures, internal quality
assurance processes, and proprietary management technology systems,
which ensure the highest quality for all aspects of the study.
Consumers can find out more about Medicus at :
http://www.medicusresearch.com/
Prior to this clinical trial Manzo Pharmaceuticals and Celprogen
will run a small pilot study with a limited number of human
subjects to make sure the dose is adequate and that no
modifications in the study need to be made before commencing the
formal in depth human clinical study. Once a successful human study
is completed, Lacto-Freedom probiotic can go to market, and the
company feels confident that it will change the lives of those
suffering from lactose intolerance. Manzo Pharmaceuticals
anticipates a successful human study and is already in talks with
several manufacturers of probiotics to be ready to go straight to
market.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the research, development, and testing of patented and
non-patented solutions and remedies. Most notably is a patented
solution for lactose Intolerance, and a natural remedy for colic in
babies. For more information follow the company on twitter at
@manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. The Company has tried, whenever possible, to identify
these forward-looking statements using words such as "anticipates,"
"believes," "estimates," "expects," "plans," "intends," "potential"
and similar expressions. These statements reflect the Company's
current beliefs and are based upon information currently available
to it. Accordingly, such forward-looking statements involve known
and unknown risks, uncertainties and other factors which could
cause the Company's actual results, performance or achievements to
differ materially from those expressed in or implied by such
statements. The Company undertakes no obligation to update or
advise in the event of any change, addition or alteration to the
information catered in this Press Release including such
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/manzo-pharmaceuticals-announces-plans-for-human-clinical-studies-of-the-companys-patented-lactose-intolerance-probiotic-lacto-freedom-300048514.html
SOURCE Manzo Pharmaceuticals, Inc.